PPMS

Crew-8 Astronauts to Support Variety of R&D Projects During Six-Month Science Expedition

Retrieved on: 
Monday, February 26, 2024
Therapy, PPMS, Redwire, PIL, Commercial Resupply Services, NASA, ProLiant, SpaceX launch vehicles, EST, 3D, Growth, Cell, Commercial Crew Program, Medication, Life, Eli Lilly and Company, Laboratory, HPE, ISS, ISS National Lab, SPACE, Emory University, Butler University, Gene, Kennedy Space Center, SpaceX, Boeing, Patient, Hewlett Packard Enterprise, International Space Station, Communications satellite

Findings will help advance cardiac disease modeling and could lead to the development of new therapies to treat heart disease in patients on Earth.

Key Points: 
  • Findings will help advance cardiac disease modeling and could lead to the development of new therapies to treat heart disease in patients on Earth.
  • Results from this could lead to improved therapeutics to treat an array of conditions.
  • A project from the National Stem Cell Foundation (NSCF) will continue to study the mechanisms behind neuroinflammation, a common feature of neurodegenerative diseases.
  • Boeing partnered with NASA and the ISS National Lab, launching an investigation testing protocols for future Genes in Space™ student-led investigations.

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy

Retrieved on: 
Tuesday, January 30, 2024
Partnership, WSA, Medical school, Inflammation, Holocene, PTG, Cell, Multiple sclerosis, Immune system, Trial of the century, International Centre, Clinical trial, Therapy, Patient, Institute of technology, White, Frontiers, PPMS, RRMS, Disease, Science, University, Health, ALS, Autoimmune disease, University of Birmingham, Warsaw Stock Exchange, Pharmaceutical industry

PolTREG was the first company in the world to administer T-reg therapies to patients and the first to start receiving revenues from its lead product.

Key Points: 
  • PolTREG was the first company in the world to administer T-reg therapies to patients and the first to start receiving revenues from its lead product.
  • So far, PolTREG has successfully treated 27 patients with PTG-007 commercially under a hospital exemption program in Poland, where the company is completing its own state-of-the-art manufacturing facilities.
  • When found in the body, Treg cells are polyclonal, meaning they can react to a number of different antigenic triggers.
  • PolTREG (Gdańsk, Poland; WSA:PTG) is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs).

Stem Cell-Derived Brain Organoids on Ax-3 Mission Seek to Improve Modeling for Neurodegenerative Diseases

Retrieved on: 
Wednesday, January 17, 2024
Patient, Axiom Space, Research, Cell, Drug discovery, Environment, Organoid, CRS, Alzheimer's disease, Central nervous system, Microglia, PPMS, Therapy, Inflammation, Commercial Resupply Services, ISS National Lab, Clinical trial, Brain, Ageing, SpaceX, Pharmaceutical industry

The mission will mark the fifth flight to the orbiting laboratory for NSCF, which is aiming to study tissue changes within stem cell-derived brain organoids to pinpoint where inflammation begins in the brain.

Key Points: 
  • The mission will mark the fifth flight to the orbiting laboratory for NSCF, which is aiming to study tissue changes within stem cell-derived brain organoids to pinpoint where inflammation begins in the brain.
  • To that end, NSCF will send human brain organoids derived from patients with two different types of degenerative brain diseases— Parkinson's and PPMS —to the orbiting laboratory.
  • Approximately 80 organoids will be studied over the two-week mission before being returned to Earth and to NSCF for further analysis.
  • A follow-on investigation will fly on SpaceX's upcoming 30th Commercial Resupply Services (CRS) mission, currently slated for launch in March.

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

Retrieved on: 
Tuesday, January 16, 2024
WSA, Patient, Research, Medical school, Multiple sclerosis, Partnership, Element, Autoimmune disease, Graft-versus-host disease, PTG, Immune system, Cell, PPMS, Hospital, Therapy, Inflammation, RRMS, Patent, White, Warsaw Stock Exchange, Trial of the century, Pharmaceutical industry

The US allowance constitutes an important addition to the intellectual property portfolio covering PolTREG’s autoimmune therapies.

Key Points: 
  • The US allowance constitutes an important addition to the intellectual property portfolio covering PolTREG’s autoimmune therapies.
  • Many of PolTREG’s patent submissions are primary in the field, given that its team performed the first-in-human trials with Treg cell therapies in graft-versus-host disease in 2007-2009.
  • Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready to start Phase 2/3 clinical testing, upon partnership.
  • PolTREG also is developing engineered Tregs, including CAR-Tregs, antigen-specific Tregs and TCR-Tregs, all of which are in the preclinical stage.

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Retrieved on: 
Wednesday, December 6, 2023
Interferon, Risk, Tokyo Stock Exchange, Disability, Multiple sclerosis, Patent, PPMS, SPMS, MD, Code, MPH, Patient, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.
  • The allowed claims cover MN-166 (ibudilast) and interferon-beta administered in separate dosage forms, administered in the same dosage form, administered simultaneously, or administered consecutively.
  • The allowed claims specifically cover the treatment of both primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
  • The U.S. Patent and Trademark Office previously granted a similar patent covering this combination for the treatment of progressive MS."

Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing Multiple Sclerosis at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023

Retrieved on: 
Tuesday, October 10, 2023
Congress, Mount Sinai, RMS, PPMS, NESS, Great America Committee, MS, Treatment, Multiple sclerosis, Safety, Principal, Conditional sentence, GA, Research, New Drug Application, Glatiramer acetate, Department of Neurology, Xuanwu hospital, Conference, Icahn School of Medicine at Mount Sinai, Patient, Pharmaceutical industry

Multiple sclerosis (MS) is a chronic disease requiring lifelong therapy.

Key Points: 
  • Multiple sclerosis (MS) is a chronic disease requiring lifelong therapy.
  • Glatiramer acetate (GA) long-acting injection (GA Depot) consists of extended-release GA, administered once every 28 days.
  • Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma said, “We are progressing with our New Drug Application for GA Depot for the treatment of RMS.
  • The ECTRIMS-ACTRIMS meeting is an important forum to share with the neurological and investor community that GA Depot may offer an effective treatment option to patients with relapsing forms of multiple sclerosis."

EQS-News: Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Retrieved on: 
Tuesday, October 17, 2023
Calcium, SPMS, PPMS, MS, EDSS, EBioMedicine, GFAP, Magnetic resonance imaging, Disease, Teaching hospital, Webcast, RRMS, Patient, MRI, AFL, University Hospital of Basel, PMS, PIRA, Disability, Silviculture, Medical imaging, Pharmaceutical industry, Short course immune induction therapy

Serum NfL responses were consistently observed for vidofludimus calcium across progressive MS disease and all subpopulations.

Key Points: 
  • Serum NfL responses were consistently observed for vidofludimus calcium across progressive MS disease and all subpopulations.
  • At 48 weeks (N=79), vidofludimus calcium reduced serum NfL by 10.4% from baseline, compared to a 6.4% increase in placebo.
  • Although early, interim GFAP data also showed a promising signal: at 24 weeks (N=203), GFAP increased by 3.7% for vidofludimus calcium, and 4.4% for placebo.
  • Top-line data from the phase 2 CALLIPER trial of vidofludimus calcium in PMS is expected in April of 2025.

Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis

Retrieved on: 
Friday, October 13, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Cerebrospinal fluid, Common, RMS, PPMS, MS, Treatment, Brain, Roche, ROG, Central nervous system, Odds ratio, Great America Committee, Multiple sclerosis, Safety, Disease, Headache, CSF, RO, Research, BTK, Patient, Pharmaceutical industry, Medical imaging, Genentech, Phase

The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis).

Key Points: 
  • The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis).
  • After 12 weeks of continuous treatment, the mean fenebrutinib concentration was 43.1 ng/mL.
  • Thus, the level of fenebrutinib in the brain and central nervous system may conceivably become high enough to reduce MS disease activity and progression.
  • The safety profile of fenebrutinib was consistent with previous and ongoing fenebrutinib clinical trials across more than 2,500 people to date.

New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided

Retrieved on: 
Thursday, October 12, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Walking, HIV disease progression rates, RMS, PPMS, Oles, MS, Infant, Treatment, Roche, Great America Committee, ROG, Weill Institute for Cell and Molecular Biology, Risk, Multiple sclerosis, University, Immunoglobulin G, OPERA, RO, DMT, CDP, Disability, Woman, Birth, Patient, Infection, Pharmaceutical industry, Genentech

In patients with PPMS, 36% were free from disability progression based on 48-week CDP events and 80% of those patients treated continuously with Ocrevus over 10 years were still able to walk.

Key Points: 
  • In patients with PPMS, 36% were free from disability progression based on 48-week CDP events and 80% of those patients treated continuously with Ocrevus over 10 years were still able to walk.
  • The risk characteristics of Ocrevus in the all-exposure population (RMS and PPMS) remained consistent with the characteristics observed during the controlled treatment periods.
  • Outcomes were known for 1,145 prospectively reported pregnancies and 512 of these had in utero exposure to Ocrevus.
  • There are more than 30 ongoing Ocrevus clinical trials designed to help us better understand MS and its progression.

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

Retrieved on: 
Wednesday, October 11, 2023
Stem Cells, Biotechnology, FDA, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, RMS, PPMS, Treatment, Roche, Great America Committee, ROG, Multiple sclerosis, Patient, Phase, IV, RO, MRI, Blood, Serum, Physician, Poster, Pharmaceutical industry, Medical device, Medical imaging, Genentech, Ocrelizumab

Study results demonstrate the effect of Ocrevus® (ocrelizumab) as an investigational twice-yearly, 10-minute subcutaneous injection on pharmacokinetic, biomarker, and MRI measures in patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS).

Key Points: 
  • Study results demonstrate the effect of Ocrevus® (ocrelizumab) as an investigational twice-yearly, 10-minute subcutaneous injection on pharmacokinetic, biomarker, and MRI measures in patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS).
  • “We are pleased to share that Ocrevus 10-minute subcutaneous injection suppressed brain lesions as effectively as the intravenous infusion,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.
  • Peak Ocrevus blood (serum) concentrations were similar for subcutaneous injection (132 µg/mL) and IV infusion (137 µg/mL).
  • Ocrevus subcutaneous injection provided rapid, sustained and near-complete B-cell depletion that was similar to Ocrevus IV infusion (97% and 98% of patients respectively had B cell levels of 5 cells/µL or less when first measured at 14 days), which was sustained over 24 weeks.